PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL

• Antonio Maria Risitano,
• David J Araten,
• David Kuter,
• Bhumika J Patel,
• Régis Peffault de Latour,
• Marion Dahlke,
• Tania Garito,
• Shujie LI,
• Samopriyo Maitra,
• Austin Kulasekararaj

Affiliations

Antonio Maria Risitano

1 AORN Moscati, Avellino, Italy

David J Araten

3 NYU Langone Medical Center, New York, New York, United States

David Kuter

5 Massachusetts General Hospital, Boston, Massachusetts, United States

Bhumika J Patel

7 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States

Régis Peffault de Latour

8 French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

Marion Dahlke

10 Novartis Pharma AG, Basel, Switzerland

Tania Garito

10 Novartis Pharma AG, Basel, Switzerland

Shujie LI

11 China Novartis Institutes for BioMedical Research Co Ltd, Shanghai, China

Samopriyo Maitra

12 Novartis Healthcare Private Limited, Hyderabad, India

Austin Kulasekararaj

13 King’s College Hospital NHS, London, United Kingdom